WS #12247
FDA approved Merck's first-in-class oral PCSK9 inhibitor Lipfendra for cholesterol, threatening Amgen's injectable PCSK9 franchise and potentially reshaping the lipid-lowering market.
FDA Approves Merck Oral PCSK9 Pill
FDA approved Merck's first-in-class oral PCSK9 inhibitor Lipfendra for cholesterol, threatening Amgen's injectable PCSK9 franchise and potentially reshaping the lipid-lowering market.